VANCOUVER, BC – Filament Health Corp. (OTCQB:FLHLF) (Cboe CA:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, announced that it has entered into agreements with Negev Capital Fund One,… Read More
VANCOUVER, BC – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, announced that… Read More
Cancer incidence is expected to rise significantly through 2050, particularly in lower-income countries, to 32 million new cases annually – a potential increase of more than 12 million new annual… Read More
Research and development (R&D) play a crucial role in improving the health and well-being of patients all over the world. It leads to the development of new technologies and procedures… Read More
VANCOUVER, BC – Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial evaluating a new immunomodulator designed to strengthen natural… Read More
